Department of Pharmacology

Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.

Thanks to major funding from the National Institutes of Health (NIH), researchers at Vanderbilt University Medical Center have made major inroads in understanding how high-density lipoprotein (HDL), commonly known as good cholesterol, in some cases may actually contribute to the development of atherosclerosis.

An innovative Vanderbilt program that brings together scientists and artists with the shared goal of scientific communication is set to expand with support from a three-year grant from the Burroughs Wellcome Fund.

Tina Iverson and colleagues provide a structural view into the assembly of a protein machine essential for cellular energy production.

A small-molecule “scavenger” that reduces inflammation and formation of atherosclerotic plaque in blood vessels in mice potentially could lead to a new approach for treating atherosclerosis in humans, according to researchers at Vanderbilt University Medical Center.

After serving 16 years as associate director for Research Education at Vanderbilt-Ingram Cancer Center (VICC), Ann Richmond, PhD, Ingram Professor of Cancer Research, is stepping down from the leadership post.

Vanderbilt researchers have identified and characterized inhibitors of an enzyme that synthesizes lipid signaling molecules with roles in energy balance, inflammation and addiction.